PR Newswire BiotechOriginal article
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Phase 2RAG-17Positive
AI Analysis
Summary
Ractigen Therapeutics announced completion of patient enrollment and initial dosing in its Phase II clinical trial of RAG-17 for SOD1-ALS, a next-generation RNA therapeutic.
Clinical Trial Data
Phase
Phase II
Outcome Details
Completion of patient enrollment and first dosing across all cohorts
Importance:5/10
Sentiment:
0.50
RNA therapeuticsALSclinical trialPhase 2enrollment complete
Read the original article
Published by PR Newswire Biotech on August 6, 2026 11:30 AM